Streetbeat News

VCXB

10X Capital Venture Acquisition Corp III

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

10X Capital Venture Acquisition Corp. III has received a notice from the NYSE for failing to file its Form 10-K on time. This notice is a standard procedure for companies that do not meet the NYSE's filing deadlines. The company is expected to address this issue promptly to remain in compliance with NYSE listing requirements.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:44 pm

10X Capital Venture Acquisition Corp. has received a notice from the NYSE indicating that it is not in compliance with the exchange's listing standards. The specific standards not met were not disclosed in the news snippet provided.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 10:47 pm

10X Capital Venture Acquisition Corp. III (10X III) announced that COO David Weisburd is expected to become CEO, succeeding Hans Thomas, subject to board approval. Osman Ahmed is expected to take over as President from Oliver Wriedt. Hans Thomas will continue as Chairman of the board.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:17 am

10X Capital Venture Acquisition Corp. III (VCXB) received a notice from NYSE for not filing its Q3 Form 10-Q on time. The delay was due to the accounting firm requiring more time to review financial statements. VCXB has since filed the report and regained compliance with NYSE listing standards.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 9:26 pm

10X Capital Venture Acquisition has transferred its listed securities to the NYSE American. The company's ticker symbol, VCXB, remains the same.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 5:50 am

Clinical stage gene therapy company, Addimmune, is set to go public through a business combination with SPAC 10x Capital Venture Acquisition Corp. III (VCXB).

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 5:55 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.